Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection | Zendy

Jesica A. Herrick | Zendy; Fanny Legrand | Zendy; Racéline Kamkumo Gounoue | Zendy; Godwin Nchinda | Zendy; Céline Montavon | Zendy; Jean Bopda | Zendy; Steve Mbickmen Tchana | Zendy; Bienvenu Etogo Ondigui | Zendy; Konrad Nguluwe | Zendy; Michael P. Fay | Zendy; Michelle Makiya | Zendy; Simon Metenou | Zendy; Thomas B. Nutman | Zendy; Joseph Kamgno | Zendy; Amy D. Klion | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Posttreatment Reactions After Single-Dose Diethylcarbamazine or Ivermectin in Subjects With Loa loa Infection

Author(s) -

Jesica A. Herrick,

Fanny Legrand,

Racéline Kamkumo Gounoue,

Godwin Nchinda,

Céline Montavon,

Jean Bopda,

Steve Mbickmen Tchana,

Bienvenu Etogo Ondigui,

Konrad Nguluwe,

Michael P. Fay,

Michelle Makiya,

Simon Metenou,

Thomas B. Nutman,

Joseph Kamgno,

Amy D. Klion

Publication year - 2017

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cix016

Subject(s) - ivermectin , loa loa , diethylcarbamazine , medicine , onchocerciasis , eosinophil , lymphatic filariasis , adverse effect , lymphocyte , immunology , pathophysiology , gastroenterology , physiology , filariasis , veterinary medicine , helminths , asthma

Severe adverse reactions have been observed in individuals with Loa loa infection treated with either diethylcarbamazine (DEC), the drug of choice for loiasis, or ivermectin (IVM), which is used in mass drug administration programs for control of onchocerciasis and lymphatic filariasis in Africa. In this study, posttreatment clinical and immunologic reactions were compared following single-dose therapy with DEC or IVM to assess whether these reactions have the same underlying pathophysiology.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research